Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Effects of Cabozantinib Alone and in Combination with Bortezomib in the 5TGM1 Murine Multiple Myeloma Model

Dana T. Aftab, PhD, Mari I. Suominen, Douglas O. Clary, PhD, Rami Käkönen, Katja M. Fagerlund, Esa Alhoniemi, Jukka P. Rissanen, Jussi M. Halleen

Blood (2014) 124 (21): 3442.

https://doi.org/10.1182/blood.V124.21.3442.3442

Published: 2014

Journal Articles

A Phase I Study of XL019, a Selective JAK2 Inhibitor, in Patients with Polycythemia Vera

Ronald Paquette, MD, Lubomir Sokol, MD, PhD, Neil P. Shah, MD, PhD, Richard T. Silver, MD, Alan F. List, MD, Douglas O. Clary, Lynne A. Bui, MD, Moshe Talpaz, MD

Blood (2008) 112 (11): 2810.

https://doi.org/10.1182/blood.V112.11.2810.2810

Published: 2008

Journal Articles

EXEL-8232, a Small Molecule JAK2 Inhibitor, Effectively Treats Thrombocytosis and Extramedullary Hematopoiesis in a Murine Model of Myeloproliferative Disease Induced by MPLW515L

Gerlinde Wernig, Michael G. Kharas, Dena S. Leeman, Rachel Okabe, Maricel Gozo, Mahnaz Paktinat, Erika Haydu, Brian Ball, Tulasi Khandan, Douglas O. Clary, D Gary Gilliland

Blood (2008) 112 (11): 3741.

https://doi.org/10.1182/blood.V112.11.3741.3741

Published: 2008

Journal Articles

Preliminary Clinical Activity in a Phase I Trial of the BCR-ABL/IGF- 1R/Aurora Kinase Inhibitor XL228 in Patients with Ph + + Leukemias with Either Failure to Multiple TKI Therapies or with T315I Mutation

Jorge Cortes, MD, Ronald Paquette, MD, Moshe Talpaz, Javier Pinilla, MD, PhD, Ekatherine Asatiani, MD, Meir Wetzler, MD, Jeffrey H. Lipton, MD, PhD, Corynn Kasap, BS, Lynne A. Bui, MD, Douglas O. Clary, PhD, Neil Shah, MD, PhD

Blood (2008) 112 (11): 3232.

https://doi.org/10.1182/blood.V112.11.3232.3232

Published: 2008

Journal Articles

A Phase I Study of XL019, a Selective JAK2 Inhibitor, in Patients with Primary Myelofibrosis, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis

Neil P. Shah, MD, PhD, Patrycja Olszynski, Lubomir Sokol, MD, PhD, Srdan Verstovsek, Ronald Hoffman, MD, Alan F. List, MD, Jorge Cortes, MD, Hagop M Kantarjian, D. Gary Gilliland, Douglas O Clary, PhD, Lynne A. Bui, MD, Martha Wadleigh, MD

Blood (2008) 112 (11): 98.

https://doi.org/10.1182/blood.V112.11.98.98

Published: 2008

Journal Articles

Targeting Drug-Resistant CML and Ph+-ALL with the Spectrum Selective Protein Kinase Inhibitor XL228.

Neil P. Shah, Corynn Kasap, Ronald Paquette, Jorge Cortes, Javier Pinilla, Moshe Talpaz, Lynne A. Bui, Douglas O. Clary

Blood (2007) 110 (11): 474.

https://doi.org/10.1182/blood.V110.11.474.474

Published: 2007

Journal Articles

A Phase I Study of XL019, a Selective JAK2 Inhibitor, in Patients with Primary Myelofibrosis and Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis.

Srdan Verstovsek, Animesh D. Pardanani, Neil P. Shah, Lubomir Sokol, Martha Wadleigh, D. Gary Gilliland, Alan F. List, Ayalew Tefferi, Hagop M. Kantarjian, Lynne A. Bui, Douglas O. Clary

Blood (2007) 110 (11): 553.

https://doi.org/10.1182/blood.V110.11.553.553

Published: 2007

NARROW

Effects of Cabozantinib Alone and in Combination with Bortezomib in the 5TGM1 Murine Multiple Myeloma Model

A Phase I Study of XL019, a Selective JAK2 Inhibitor, in Patients with Polycythemia Vera

EXEL-8232, a Small Molecule JAK2 Inhibitor, Effectively Treats Thrombocytosis and Extramedullary Hematopoiesis in a Murine Model of Myeloproliferative Disease Induced by MPLW515L

Preliminary Clinical Activity in a Phase I Trial of the BCR-ABL/IGF- 1R/Aurora Kinase Inhibitor XL228 in Patients with Ph + + Leukemias with Either Failure to Multiple TKI Therapies or with T315I Mutation

A Phase I Study of XL019, a Selective JAK2 Inhibitor, in Patients with Primary Myelofibrosis, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis

Targeting Drug-Resistant CML and Ph+-ALL with the Spectrum Selective Protein Kinase Inhibitor XL228.

A Phase I Study of XL019, a Selective JAK2 Inhibitor, in Patients with Primary Myelofibrosis and Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis.

Email alerts

ASH Publications

American Society of Hematology

Effects of Cabozantinib Alone and in Combination with Bortezomib in the 5TGM1 Murine Multiple Myeloma Model

A Phase I Study of XL019, a Selective JAK2 Inhibitor, in Patients with Polycythemia Vera

EXEL-8232, a Small Molecule JAK2 Inhibitor, Effectively Treats Thrombocytosis and Extramedullary Hematopoiesis in a Murine Model of Myeloproliferative Disease Induced by MPLW515L

Preliminary Clinical Activity in a Phase I Trial of the BCR-ABL/IGF- 1R/Aurora Kinase Inhibitor XL228 in Patients with Ph + + Leukemias with Either Failure to Multiple TKI Therapies or with T315I Mutation

A Phase I Study of XL019, a Selective JAK2 Inhibitor, in Patients with Primary Myelofibrosis, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis

Targeting Drug-Resistant CML and Ph+-ALL with the Spectrum Selective Protein Kinase Inhibitor XL228.

A Phase I Study of XL019, a Selective JAK2 Inhibitor, in Patients with Primary Myelofibrosis and Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only